Decreased diabetes risk over 9 year after 18-month oral L-arginine treatment in middle-aged subjects with impaired glucose tolerance and metabolic syndrome (extension evaluation of L-arginine study)
Lucilla D Monti, Elena Galluccio, Valentina Villa, Barbara Fontana, Serena Spadoni, Pier Marco Piatti, Lucilla D Monti, Elena Galluccio, Valentina Villa, Barbara Fontana, Serena Spadoni, Pier Marco Piatti
Abstract
Purpose: This study aimed to determine whether L-arginine supplementation lasting for 18 months maintained long-lasting effects on diabetes incidence, insulin secretion and sensitivity, oxidative stress, and endothelial function during 108 months among subjects at high risk of developing type 2 diabetes.
Methods: One hundred and forty-four middle-aged subjects with impaired glucose tolerance and metabolic syndrome were randomized in 2006 to an L-arginine supplementation (6.4 g orally/day) or placebo therapy lasting 18 months. This period was followed by a 90-month follow-up. The primary outcome was a diagnosis of diabetes during the 108 month study period. Secondary outcomes included changes in insulin secretion (proinsulin/c-peptide ratio), insulin sensitivity (IGI/HOMA-IR), oxidative stress (AOPPs), and vascular function. After the 18 month participation, subjects that were still free of diabetes and willing to continue their participation (104 subjects) were further followed until diabetes diagnosis, with a time span of about 9 years from baseline.
Results: Although results derived from the 18 month of the intervention study demonstrated no differences in the probability of becoming diabetics, at the end of the study, the cumulative incidence of diabetes was of 40.6% in the L-arginine group and of 57.4% in the placebo group. The adjusted HR for diabetes (L-arginine vs. placebo) was 0.66; 95% CI 0.48, 0.91; p < 0.02). Proinsulin/c-peptide ratio (p < 0.001), IGI/HOMA-IR (p < 0.01), and AOPP (p < 0.05) levels were ameliorated in L-arginine compared to placebo.
Conclusions: These results may suggest that the administration of L-arginine could delay the development of T2DM for a long period. This effect could be mediated, in some extent, by L-arginine-induced reduction in oxidative stress.
Trial registration: ClinicalTrials.gov NCT00917449.
Keywords: Endothelial function; Insulin secretion; L-Arginine; Oxidative stress; Prevention of type 2 diabetes.
Conflict of interest statement
Conflict of interestThe authors declare that they have no conflict of interest.
GrantsFunding Italian Ministry of Health, Finalizzata no. 88, 2004.
Figures
References
- Portero McLellan KC. Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag. 2014;10:173–188.
- Diabetes Prevention Program (DPP) Research Group The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007;24:137–144. doi: 10.1111/j.1464-5491.2007.02043.x.
- Ford ES. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010;55:1310–1317. doi: 10.1016/j.jacc.2009.10.060.
- Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–110. doi: 10.2337/diabetes.52.1.102.
- Pfützner A, Kann PH, Pfützner AH, et al. Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance. Clin Lab. 2004;50:567–573.
- Li M, Dou L, Jiao J, et al. NADPH oxidase 2-devied reactive oxygen species are involved on dysfunction and apoptosis of pancreatic β-cells induced by low density lipoprotein. Cell Physiol Biochem. 2012;30:439–449. doi: 10.1159/000339037.
- Liang M, Li A, Lou A, et al. Advanced oxidation protein products promote NAPDH oxidase-dependent β-cell destruction and dysfunction through the Bcl-2/Bax apoptotic pathway. Lab Investig. 2017 doi: 10.1038/labinvest.2017.24.
- Wilcox CS. Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables. Hypertension. 2012;59:375–381. doi: 10.1161/HYPERTENSIONAHA.111.187310.
- Cardounel AJ, Cui H, Samouilov A, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem. 2007;282:879–898. doi: 10.1074/jbc.M603606200.
- Awad O, Jiao C, Ma N, Dunnwald M, Schatteman GC. Obese diabetic mouse environment differentially affects primitive and monocytic endothelial cell progenitors. Stem Cells. 2005;23:575–583. doi: 10.1634/stemcells.2004-0185.
- Cubbon RM, Kahn MB, Wheatcroft SB. Effects of insulin resistance on endothelial progenitor cells and vascular repair. Clin Sci (Lond) 2009;117:173–190. doi: 10.1042/CS20080263.
- Visek WJ. Arginine needs, physiologic state and usual diets. A reevaluation. J Nutr. 1986;116:36–46. doi: 10.1093/jn/116.1.36.
- Wells BJ, Mainous AG, III, Everett CJ. Association between dietary arginine and C-reactive protein. Nutrition. 2005;21:125–130. doi: 10.1016/j.nut.2004.03.021.
- Wu G, Bazer FW, Davis TA, et al. Arginine metabolism and nutrition in growth, health and disease. Amino Acids. 2009;37:153–168. doi: 10.1007/s00726-008-0210-y.
- Wascher TC, Graier WF, Dittrich P, et al. Effects of low-dose l-arginine on insulin-mediated vasodilatation and insulin sensitivity. Eur J Clin Investig. 1997;27:690–695. doi: 10.1046/j.1365-2362.1997.1730718.x.
- Boger RH. The pharmacodynamics of l-arginine. J Nutr. 2007;137:1650S–1655S. doi: 10.1093/jn/137.6.1650S.
- Piatti PM, Monti LD, Valsecchi G, et al. Long-term oral l-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care. 2001;24:875–880. doi: 10.2337/diacare.24.5.875.
- Lucotti P, Setola E, Monti LD, et al. Beneficial effects of a long-term oral l-arginine added to a hypocaloric diet and exercise training program in obese, insulin-resistant 2 diabetic patients. Am J Physiol Endocrinol Metab. 2006;291:E906–E912. doi: 10.1152/ajpendo.00002.2006.
- Lucotti P, Monti L, Setola E, et al. Oral l-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aorto-coronary bypass. Metabolism. 2009;58:1270–1276. doi: 10.1016/j.metabol.2009.03.029.
- Monti LD, Setola E, Lucotti PC, et al. Effect of a long-term oral l-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2012;14:893–900. doi: 10.1111/j.1463-1326.2012.01615.x.
- Mendez JD, Hernández Rde H. l-Arginine and polyamine administration protect b-cells against alloxan diabetogenic effect in Sprague–Dawley rats. Biomed Pharmacol. 2005;59:283–289. doi: 10.1016/j.biopha.2005.05.006.
- Vasilijevic A, Buzadzic B, Korac A, Petrovic V, Jankovic A, Korac B. Beneficial effects of l-arginine–nitric oxide-producing pathway in rats treated with alloxan. J Physiol. 2007;584:921–933. doi: 10.1113/jphysiol.2007.140277.
- Shi XY, Hou FF, Niu HX, et al. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal adenine dinucleotide phosphate oxidase. Endocrinology. 2008;149:1829–1839. doi: 10.1210/en.2007-1544.
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi: 10.1007/BF00280883.
- Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, the American Diabetes Association GENNID Study Group et al. Beta-cell function in a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US. Diabetes. 2002;51:2170–2178. doi: 10.2337/diabetes.51.7.2170.
- Lyssenko V, Almgren P, Anevski D, Botnia study group et al. Predictors of and Longitudinal Changes in Insulin Sensitivity and Secretion Preceding Onset of Typer 2 Diabetes. Diabetes. 2005;54:166–174. doi: 10.2337/diabetes.54.1.166.
- Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HC, Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) Investigators Effect of rosiglitazone and ramipril on beta-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care. 2010;33:608–613. doi: 10.2337/dc09-1579.
- Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function and cardiovascular risk. N Engl J Med. 2003;348:593–600. doi: 10.1056/NEJMoa022287.
- Topolski TD, LoGerfo J, Patrick DL, Williams B, Walwick J, Patrick MB. The Rapid Assessment of Physical Activity (RAPA) Among Older Adults. Prev Chronic Dis. 2006;3:1.
- Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–544. doi: 10.2337/diacare.20.4.537.
- DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551–1562. doi: 10.1056/NEJMoa065061.
- Tuomilehto J, Lindstrom J, Eriksson JG, Finnish Diabetes Prevention Study Group et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350. doi: 10.1056/NEJM200105033441801.
- Diabetes Prevention Program Research Group. Knowler WC, Fowler SE, Hamman RF, et al. 10-year Follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–1686. doi: 10.1016/S0140-6736(09)61457-4.
- Shan L, Wang B, Gao G, Cao W, Zhang Y. l-Arginine supplementation improves antioxidant defenses through l-arginine/nitric oxide pathways in exercised rats. J Appl Physiol. 2013;115:1146–1155. doi: 10.1152/japplphysiol.00225.2013.
- Lass A, Suessnbacher A, Wolkart G, Mayer B, Brunner F. Functional and analytical evidence for scavenging of oxygen radicals by l-arginine. Mol Pharmacol. 2002;61:1081–1088. doi: 10.1124/mol.61.5.1081.
- Newsholme P, Cruzat V, Arfuso F, Keane K. Nutrient regulation of insulin secretion and action. J Endocrinol. 2014;221:R105–R120. doi: 10.1530/JOE-13-0616.
- Krause MS, McClenaghan NH, Flatt PR, de Bittencourt PI, Murphy C, Newsholme P. l-arginine is essential for pancreatic beta-cell functional integrity, metabolism and defense from inflammatory challenge. J Endocrinol. 2011;211:87–97. doi: 10.1530/JOE-11-0236.
- Mykkänen L, Haffner SM, Hales CN, Rönnemaa T, Laakso M. The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes. 1997;46:1990–1995. doi: 10.2337/diab.46.12.1990.
- Zethelius B, Hales CN, Lithell HO, Berne C. Insulin resistance, impaired early insulin response, and insulin propeptides as predictors of the development of type 2 diabetes: a population-based, 7-year follow-up study in 70-year-old men. Diabetes Care. 2004;6:1433–1438. doi: 10.2337/diacare.27.6.1433.
- Araujo TR, Freitas IN, Vettorazzi JF, et al. Benefits of l-alanine or l-arginine supplementation against adiposity and glucose intolerance in monosodium glutamate-induced obesity. Eur J Nutr. 2016 doi: 10.1007/s00394-016-1245-6.
- Tepper OM, Galiano RD, Capla JM, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002;106:2781–2786. doi: 10.1161/01.CIR.0000039526.42991.93.
- Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005;45:1449–1457. doi: 10.1016/j.jacc.2004.11.067.
- Fadini GP, Pucci L, Vanacore R, et al. Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia. 2007;50:2156–2163. doi: 10.1007/s00125-007-0732-y.
- Yue WS, Lau KK, Siu CW, et al. Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2011;10:113. doi: 10.1186/1475-2840-10-113.
- Schernthaner G, Krzyzanowska K. Role of asymmetric dimethylarginine in cardiovascular disease and diabetes. Biomarkers Med. 2008;2:317–320. doi: 10.2217/17520363.2.4.317.
- Surdacki A, Kruszelnicka O, Rakowski T, Jaźwińska-Kozuba A, Dubiel JS. Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study. Cardiovasc Diabetol. 2013;12:64. doi: 10.1186/1475-2840-12-64.
- Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–2167. doi: 10.1001/jama.290.16.2159.
- Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med. 2008;359:1618–1620. doi: 10.1056/NEJMe0807625.
- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589. doi: 10.1056/NEJMoa0806470.
- McCullough ML, Karanja NM, Lin PH, et al. Comparison of 4 nutrient databases with chemical composition data from the Dietary Approaches to Stop Hypertension Trial. DASH Collaborative Research Group. J Am Diet Assoc. 1999;99(suppl 8S):S45–S53. doi: 10.1016/S0002-8223(99)00416-2.
Source: PubMed